Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030, Diabetes Care, vol.27, issue.5, pp.1047-1053, 2004. ,
DOI : 10.2337/diacare.27.5.1047
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, vol.32, issue.1, pp.193-203, 2009. ,
DOI : 10.2337/dc08-9025
Metformin monotherapy for type 2 diabetes mellitus, Cochrane Database Syst Rev, p.2966, 2005. ,
Cardiovascular Outcomes in Trials of Oral Diabetes Medications, Archives of Internal Medicine, vol.168, issue.19, pp.2070-2080, 2008. ,
DOI : 10.1001/archinte.168.19.2070
Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations, Annals of Internal Medicine, vol.154, issue.9, pp.602-613, 2011. ,
DOI : 10.7326/0003-4819-154-9-201105030-00336
Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials, Diabetes, Obesity and Metabolism, vol.46, issue.3, pp.221-228, 2011. ,
DOI : 10.1111/j.1463-1326.2010.01349.x
Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications, European Journal of Internal Medicine, vol.13, issue.7, pp.428-433, 2002. ,
DOI : 10.1016/S0953-6205(02)00131-0
Comparative Outcomes Study of Metformin Intervention Versus Conventional Approach The COSMIC Approach Study, Diabetes Care, vol.28, issue.3, pp.539-543, 2005. ,
DOI : 10.2337/diacare.28.3.539
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?, Controlled Clinical Trials, vol.17, issue.1, pp.1-12, 1996. ,
DOI : 10.1016/0197-2456(95)00134-4
Quantifying heterogeneity in a meta-analysis, Statistics in Medicine, vol.14, issue.11, pp.1539-1558, 2002. ,
DOI : 10.1002/sim.1186
Undue reliance on I 2 in assessing heterogeneity may mislead, BMC Medical Research Methodology, vol.176, issue.8, p.79, 2008. ,
DOI : 10.1503/cmaj.060410
Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus, Archives of Internal Medicine, vol.169, issue.6, pp.616-625, 2009. ,
DOI : 10.1001/archinternmed.2009.20
Prospective randomised two-years clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes, Diabete Metab, vol.17, pp.213-217, 1991. ,
Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A double-blind controlled study, Diabetes Care, vol.17, issue.10, pp.1100-1109, 1994. ,
DOI : 10.2337/diacare.17.10.1100
Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes, Diabetes Care, vol.23, issue.11, pp.1660-1665, 2000. ,
DOI : 10.2337/diacare.23.11.1660
Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients, Diabetes, Obesity and Metabolism, vol.20, issue.Suppl., pp.428-434, 2001. ,
DOI : 10.1046/j.1463-1326.2001.00160.x
Rosiglitazone but Not Metformin Enhances Insulin- and Exercise-Stimulated Skeletal Muscle Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes, Diabetes, vol.51, issue.12, pp.3479-3485, 2002. ,
DOI : 10.2337/diabetes.51.12.3479
Efficacy of Glyburide/Metformin Tablets Compared with Initial Monotherapy in Type 2 Diabetes, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.8, pp.3598-3604, 2003. ,
DOI : 10.1210/jc.2002-021225
Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy, Diabetes, Obesity and Metabolism, vol.49, issue.6, pp.368-375, 2002. ,
DOI : 10.1007/s005920050146
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus, New England Journal of Medicine, vol.333, issue.9, pp.541-549, 1995. ,
DOI : 10.1056/NEJM199508313330902
The Synergistic Effect of Miglitol Plus Metformin Combination Therapy in the Treatment of Type 2 Diabetes, Diabetes Care, vol.24, issue.6, pp.989-994, 2001. ,
DOI : 10.2337/diacare.24.6.989
How citation distortions create unfounded authority: analysis of a citation network Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, BMJ ADVANCE Collaborative Group N Engl J Med, vol.339, issue.358, pp.2560-2572, 2008. ,
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial, The Lancet, vol.373, issue.9681, pp.2125-2135, 2009. ,
DOI : 10.1016/S0140-6736(09)60953-3
Combination therapy with sulphonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study, Pharmacoepidemiol Drug Saf, vol.19, pp.335-342, 2010. ,
Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study, Diabetologia, vol.44, issue.12, pp.2546-2553, 2010. ,
DOI : 10.1007/s00125-010-1906-6
Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study, Diabetes, Obesity and Metabolism, vol.5, issue.9, pp.757-765, 2010. ,
DOI : 10.1111/j.1463-1326.2010.01230.x
Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?: A meta-analysis of observational studies, Diabetes Care, vol.31, issue.8, pp.1672-1678, 2008. ,
DOI : 10.2337/dc08-0167
Some answers, more controversy, from UKPDS, The Lancet, vol.352, issue.9131, pp.832-833, 1998. ,
DOI : 10.1016/S0140-6736(98)22937-0
The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study Commentary: UKPDS is well designed and clinically important, BMJ, vol.323, issue.7317, pp.854-858, 2001. ,
DOI : 10.1136/bmj.323.7317.854
Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data, BMJ, vol.320, issue.7251, pp.1720-1723, 2000. ,
DOI : 10.1136/bmj.320.7251.1720
Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials, JAMA: The Journal of the American Medical Association, vol.273, issue.5, pp.408-412, 1995. ,
DOI : 10.1001/jama.273.5.408
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?, The Lancet, vol.352, issue.9128, pp.609-613, 1998. ,
DOI : 10.1016/S0140-6736(98)01085-X
Follow-up of intensive glucose control in type 2 diabetes. The authors reply, N Engl J Med, vol.360, pp.416-418, 2009. ,
Quantifying the Effect of Metformin Treatment and Dose on Glycemic Control, Diabetes Care, vol.35, issue.2, pp.446-454, 2012. ,
DOI : 10.2337/dc11-1465
What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes, BMJ, vol.327, issue.7409, pp.266-273, 2003. ,
DOI : 10.1136/bmj.327.7409.266
Patient-Important Outcomes in Registered Diabetes Trials, JAMA, vol.299, issue.21, pp.2543-2549, 2008. ,
DOI : 10.1001/jama.299.21.2543
Surrogate endpoints in clinical trials: Definition and operational criteria, Statistics in Medicine, vol.248, issue.4, pp.431-440, 1989. ,
DOI : 10.1002/sim.4780080407
Metformin associated lactic acidosis, BMJ, vol.339, issue.sep16 2, 2009. ,
DOI : 10.1136/bmj.b3660
Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial, BMJ, vol.340, issue.may19 4, 2010. ,
DOI : 10.1136/bmj.c2181
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database, BMJ, vol.339, issue.dec03 1, 2009. ,
DOI : 10.1136/bmj.b4731
Insulin use and increased risk of mortality in type 2 diabetes: a cohort study, Diabetes, Obesity and Metabolism, vol.25, issue.1, pp.47-53, 2010. ,
DOI : 10.1111/j.1463-1326.2009.01125.x
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review, BMJ, vol.335, issue.7618, p.497, 2007. ,
DOI : 10.1136/bmj.39314.620174.80
Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin, Diabetes Care, vol.29, issue.2, pp.254-258, 2006. ,
DOI : 10.2337/diacare.29.02.06.dc05-1558
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes, Diabetologia, vol.23, issue.9, pp.1766-1777, 2009. ,
DOI : 10.1007/s00125-009-1440-6
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes, New England Journal of Medicine, vol.356, issue.24, pp.2457-2471, 2007. ,
DOI : 10.1056/NEJMoa072761
Pioglitazone for type 2 diabetes mellitus, Cochrane Database Syst Rev, vol.15, issue.1, p.6060, 2006. ,
DOI : 10.1002/14651858.CD006060.pub2
Metformin Use and Mortality Among Patients With Diabetes and Atherothrombosis<alt-title>Metformin Use With Diabetes and Atherothrombosis</alt-title>, Archives of Internal Medicine, vol.170, issue.21, pp.1892-1899, 2010. ,
DOI : 10.1001/archinternmed.2010.409